Neuropace Total Current Assets from 2010 to 2026
| NPCE Stock | USD 15.05 0.55 3.79% |
Total Current Assets | First Reported 2020-03-31 | Previous Quarter 93.7 M | Current Value 95.3 M | Quarterly Volatility 31.6 M |
Check Neuropace financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuropace's main balance sheet or income statement drivers, such as Interest Income of 3.7 M, Depreciation And Amortization of 1.4 M or Interest Expense of 7.1 M, as well as many indicators such as Price To Sales Ratio of 4.93, Dividend Yield of 0.0 or PTB Ratio of 38.44. Neuropace financial statements analysis is a perfect complement when working with Neuropace Valuation or Volatility modules.
Neuropace | Total Current Assets | Build AI portfolio with Neuropace Stock |
Analyzing Neuropace's Total Current Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Current Assets has evolved provides context for assessing Neuropace's current valuation and future prospects.
Latest Neuropace's Total Current Assets Growth Pattern
Below is the plot of the Total Current Assets of Neuropace over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Neuropace's Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neuropace's overall financial position and show how it may be relating to other accounts over time.
| Total Current Assets | 10 Years Trend |
|
Total Current Assets |
| Timeline |
Neuropace Total Current Assets Regression Statistics
| Arithmetic Mean | 49,598,923 | |
| Geometric Mean | 37,248,779 | |
| Coefficient Of Variation | 78.31 | |
| Mean Deviation | 34,516,380 | |
| Median | 20,260,000 | |
| Standard Deviation | 38,839,754 | |
| Sample Variance | 1508.5T | |
| Range | 112.6M | |
| R-Value | 0.80 | |
| Mean Square Error | 588.8T | |
| R-Squared | 0.63 | |
| Significance | 0.0001 | |
| Slope | 6,124,683 | |
| Total Sum of Squares | 24136.4T |
Neuropace Total Current Assets History
About Neuropace Financial Statements
Neuropace stakeholders use historical fundamental indicators, such as Neuropace's Total Current Assets, to determine how well the company is positioned to perform in the future. Although Neuropace investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neuropace's assets and liabilities are reflected in the revenues and expenses on Neuropace's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neuropace. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Assets | 93.5 M | 87.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:Check out the analysis of Neuropace Correlation against competitors. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuropace diversify its offerings? Factors like these will boost the valuation of Neuropace. Anticipated expansion of Neuropace directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuropace data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets | Return On Equity |
Understanding Neuropace requires distinguishing between market price and book value, where the latter reflects Neuropace's accounting equity. The concept of intrinsic value - what Neuropace's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neuropace's price substantially above or below its fundamental value.
It's important to distinguish between Neuropace's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuropace should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neuropace's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.